Woebot Health, a San Francisco, CA-based mental health company, raised $9.5m in funding.
Leaps by Bayer, the impact investment arm of Bayer AG, made the strategic investment, which The follows Woebot Health’s $90m Series B round in 2021 and brings total investment in the company to date to $123.5m.
The company intends to use the funds to accelerate further development of its AI-powered behavioral health platform and products.
Ihe investment coincides with a collaboration between Woebot Health and Bayer Pharmaceuticals initiated as part of the G4A Digital Health Partnerships Program, for which the companies signed a Letter of Intent together with Bayer Integrated Care to assess joint opportunities on delivering integrated care solutions in mental health that ultimately improve people’s lives.
Led by Michael Evers, CEO, Woebot Health is a mental health ally for people and businesses, with products that put personal growth in people’s hands, wherever they are. The behavioral health platform combines AI, clinically-proven therapeutic research and an engaging relational agent called Woebot, which together form the foundation for delivering continuous care via purely digital, empathic and personalized apps that are easy to talk to and fit right into people’s lives.
FinSMEs
21/03/2022